7 results found for: “rinvoq”.

Request time (Page generated in 0.3471 seconds.)

Upadacitinib

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis...

Last Update: 2024-02-08T05:05:29Z Word Count : 4517

View Page View Rich Text Page View Plain Text Page

AbbVie

2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia...

Last Update: 2024-03-22T10:29:05Z Word Count : 3286

View Page View Rich Text Page View Plain Text Page

Crohn's disease

1002/14651858.CD006097.pub3. PMC 6513248. PMID 30068022. "Discover RINVOQ® (upadacitinib)". RINVOQ. Archived from the original on May 18, 2023. Retrieved May...

Last Update: 2024-03-22T13:47:19Z Word Count : 18271

View Page View Rich Text Page View Plain Text Page

Janus kinase inhibitor

1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525. "AbbVie Receives FDA Approval of Rinvoq (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe...

Last Update: 2023-11-10T21:18:15Z Word Count : 2522

View Page View Rich Text Page View Plain Text Page

CYP3A4

Machine Facts for prescribers (Fakta för förskrivare). Retrieved July 2011 "Rinvoq: EPAR – Public assessment report Archived 21 July 2020 at the Wayback Machine"...

Last Update: 2024-03-17T03:02:59Z Word Count : 7537

View Page View Rich Text Page View Plain Text Page

Atopic dermatitis

inhibitors such as abrocitinib, trade name Cibinqo, and upadacitinib, trade name Rinvoq, have been approved in the US for the treatment of moderate-to-severe eczema...

Last Update: 2024-03-14T01:51:31Z Word Count : 8359

View Page View Rich Text Page View Plain Text Page

Psoriatic arthritis

the market. The JAK1 inhibitors tofacitinib (Xeljanz) and upadacitinib (Rinvoq) are approved for the use in active psoriatic arthritis. The TYK2 inhibitor...

Last Update: 2024-03-22T02:35:14Z Word Count : 3453

View Page View Rich Text Page View Plain Text Page

Main result

Upadacitinib

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.Upadacitinib was approved for medical use in both the United States and the European Union in 2019.


Dodaje.pl - Ogłoszenia lokalne